Genomic Testing and ALK Alterations
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Genomic Testing and ALK Alterations
-
Narrated by:
-
By:
About this listen
On episode 8 of Oncology Hour, we discuss ALK alterations in cancer and genomic testing. ALK Alterations appear in lung cancer, lymphoma, and childhood cancer. ALK inhibitors are treatments that target ALK alterations in cancer patients. Today's guests are pediatric oncologists Dr. Jason Freedman and Dr. Ted Laetsch. Dr. Jason Freedman specializes in pediatric oncology and has contributed to the development of clinical guidelines to standardize management of symptoms. Dr Ted Laetsch leads clinical and translational research evaluating novel targeted and immunotherapies for children with high-risk and often ultra-rare cancers.
No reviews yet